Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Dec 6;9(1):18515.
doi: 10.1038/s41598-019-55112-y.

Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: A multicenter surveillance

Affiliations
Multicenter Study

Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: A multicenter surveillance

Mohammadreza Allahyartorkaman et al. Sci Rep. .

Abstract

Diagnostic accuracy of Xpert MTB/RIF assay for pulmonary tuberculosis (PTB) and extrapulmonary TB (EPTB) has not been investigated in Iran. This study was aimed to assess the diagnostic accuracy of Xpert MTB/RIF assay for both PTB and EPTB. A total of 2111 clinical samples (1218 pulmonary and 838 extra-pulmonary) were collected from 16 medical centers during the study period and were analyzed for detection of PTB and EPTB by both Xpert MTB/RIF assay and standard conventional methods (culture and direct smear microscopy). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Xpert MTB/RIF assay for PTB were found to be 95.5%, 96.7%, 83.8%, and 99.1% respectively. For EPTB, the sensitivity, specificity, PPV and NPV of Xpert MTB/RIF assay counted for 76.5%, 95.9%, 62%, and 97.9% respectively. Xpert MTB/RIF assay found to be highly sensitive, specific and comparable to standard conventional methods for the diagnosis of PTB. However, the sensitivity and specificity of Xpert MTB/RIF for EPTB specimens were highly variable; thus, Xpert MTB/RIF cannot be recommended to replace standard conventional tests for diagnosis of EPTB.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Forest plots give details of sensitivity, specificity, PPV, and NPV. BAL: bronchoalveolar lavage fluid, CSF: cerebrospinal fluid (Red colors are representative for pulmonary samples).
Figure 2
Figure 2
The summary receiver operating characteristic (SROC) curves for Xpert MTB/RIF assay. The SROC plot shows a summary of test performance, visual assessment of threshold effect, and heterogeneity of data in SROC space between sensitivity and specificity. The dashed blue line that is around the point estimate (blue line) shows 95% confidence region. The area under the curve (AUC), acts as an overall measure for test performance. Particularly, when AUC would be between 0.8 and 1, the accuracy is relatively high. As a matter of fact, AUC was 0.96 for pulmonary specimens in this report which represented a high level of accuracy. If SROC curve was in the upper left corner it would show the best combination of sensitivity and specificity for the diagnostic test. Part “a” and “b” are representative for pulmonary and extra-pulmonary specimens, respectively.
Figure 3
Figure 3
Quadratic regression plot to compare the Xpert MTB/RIF results with culture and smear microscopy. On Xpert MTB/RIF axis, results are categorized as 0, 1, 2, 3 and 4 which are indicated as negative, very low, low, medium and high scales, respectively. On the smear axis, results are categorized as 0, 1, 2 and 3 which are indicated as negative, 1+, 2+ and 3+ grading, respectively. On culture axis, results are categorized as 0, 1, 2, 3 and 4 which are indicated as negative, 1+, 2+, 3+ and 4+ grading, respectively. Part “a” and “b” are representative for pulmonary specimens and part “c” and “d” are representative for extra-pulmonary specimens. Regression lines showed the correlations between Xpert MTB/RIF results and culture/direct smear methods results.

References

    1. World Health Organization (WHO). Global tuberculosis report (2017).
    1. Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010;363:1005–1015. doi: 10.1056/NEJMoa0907847. - DOI - PMC - PubMed
    1. Varahram M, Nasiri MJ, Farnia P, Mozafari M, Velayati AA. A retrospective analysis of isoniazid-monoresistant tuberculosis: among Iranian pulmonary tuberculosis patients. The open microbiology journal. 2014;8:1. doi: 10.2174/1874285801408010001. - DOI - PMC - PubMed
    1. Trébucq A, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? The International Journal of Tuberculosis and Lung Disease. 2011;15:1567–1572. doi: 10.5588/ijtld.11.0392. - DOI - PubMed
    1. Dunn, J. J., Starke, J. R. & Revell, P. A. Laboratory diagnosis of Mycobacterium tuberculosis infection and disease in children. Journal of clinical microbiology, JCM. 03043-03015 (2016). - PMC - PubMed

Publication types

MeSH terms